RANDOMIZED PHASE 2 STUDY OF GUADECITABINE IN PATIENTS WITH HMA-NAIVE HIGHER RISK MYELODYSPLASTIC SYNDROMES (MDS) OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)

被引：0
|
作者：
Savona, M. R. [1 ]
Garcia-Manero, G. [2 ]
Roboz, G. J. [3 ]
Walsh, K. J. [4 ]
Kropf, P. L. [5 ]
Issa, J. P. [6 ]
O'Connell, C. L. [7 ]
Tibes, R. [8 ]
Yee, K. W. L. [9 ]
Stock, W. [10 ]
Lunin, S. [11 ]
Berdeja, J. G. [12 ]
Naim, S. [13 ]
Hao, Y. [13 ]
Azab, M. [13 ]
Kantarjian, H. [2 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Hematol & Oncol, Nashville, TN USA
[2] Univ Texas MD Anderson Canc Ctr, Leukemia, Houston, TX 77030 USA
[3] Weill Cornell NY Presbyterian Med Ctr, Leukemia, New York, NY USA
[4] Ohio State Univ, Hematol, Columbus, OH 43210 USA
[5] Fox Chase Canc Ctr, Hematol & Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[6] Temple Univ, Fels Inst, Hematol & Oncol, Philadelphia, PA 19122 USA
[7] USC, Keck Sch Med, Med, Los Angeles, CA USA
[8] Mayo Clin Arizona Scottsdale, Bone Marrow Transplant, Scottsdale, AZ USA
[9] Princess Margaret Canc Ctr, Canc Clin Res Unit, Toronto, ON, Canada
[10] Univ Chicago, Med Ctr, Hematol & Oncol, Chicago, IL 60637 USA
[11] Florida Canc Specialists, Hematol & Oncol, Inglewood, CA USA
[12] Tennessee Oncol, Sarah Cannon Res Inst, Hematol, Nashville, TN USA
[13] Astex Pharmaceut Inc, Clin Dev, Pleasanton, CA USA
来源：
LEUKEMIA RESEARCH | 2017年 / 55卷
关键词：
D O I：
10.1016/S0145-2126(17)30173-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
60
引用
收藏
页码：S40 / S41
页数：2
相关论文
共 50 条
  • [1] Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)
    Garcia-Manero, Guillermo
    Ritchie, Ellen K.
    Walsh, Katherine J.
    Savona, Michael R.
    Kantarjian, Hagop M.
    Kropf, Patricia L.
    O'Connell, Casey L.
    Tibes, Raoul
    Daver, Naval G.
    Jabbour, Elias J.
    Lunin, Scott D.
    Rosenblat, Todd L.
    Yee, Karen W. L.
    Stock, Wendy
    Griffiths, Elizabeth A.
    Mace, Joseph
    Podoltsev, Nikolai A.
    Berdeja, Jesus G.
    Issa, Jean-Pierre
    Naim, Sue
    Hao, Yong
    Azab, Mohammad
    Roboz, Gail J.
    BLOOD, 2018, 132
  • [2] Updated results from phase II study of guadecitabine for patients with higher risk myelodysplastic syndromes or chronic myelomonocytic leukemia.
    Montalban-Bravo, Guillermo
    Bose, Prithviraj
    Alvarado, Yesid
    Daver, Naval Guastad
    Ravandi, Farhad
    Borthakur, Gautam
    Takahashi, Koichi
    Andreeff, Michael
    Cortes, Jorge E.
    Dinardo, Courtney Denton
    Jabbour, Elias
    Kadia, Tapan M.
    Kornblau, Steven
    Ohanian, Maro
    Huang, Xuelin
    Nogueras-Gonzalez, Graciela M.
    Bodden, Kristy
    Pierce, Sherry
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] SYSTEMATIC REVIEW OF THERAPY USED IN HIGHER-RISK (HR) MYELODYSPLASTIC SYNDROMES (MDS) AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
    Bell, J.
    Galaznik, A.
    Huelin, R.
    Stokes, M.
    Seal, B.
    Fram, R.
    Faller, D. V.
    LEUKEMIA RESEARCH, 2017, 55 : S80 - S81
  • [4] Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
    Bewersdorf, Jan Philipp
    Zeidan, Amer M.
    CANCERS, 2021, 13 (07)
  • [5] FLT3 mutations in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML)
    Bhamidipati, Pavan Kumar
    Daver, Naval Guastad
    Kantarjian, Hagop
    Pierce, Sherry
    Daver, Roshni
    Cortes, Jorge E.
    Ravandi, Farhad
    Mathisen, Michael
    Pemmaraju, Naveen
    Nazha, Aziz
    Kadia, Tapan M.
    Jabbour, Elias
    Borthakur, Gautam
    Faderl, Stefan
    Garcia-Manero, Guillermo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] A phase 2 study of azacitidine (5-AZA) with or without birinapant in subjects with higher risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML).
    Donnellan, William Bruce
    Diez-Campelo, Maria
    Heuser, Michael
    Ritchie, Ellen K.
    Skolnik, Jeffrey
    Font, Patricia
    Komrokji, Rami S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] Incidence of myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) in Norway 1993-2006
    Schoonen, W.
    Aagnes, B.
    Bray, F.
    Hansen, S.
    Fryzek, J.
    Weiderpass, E.
    LEUKEMIA RESEARCH, 2009, 33 : S64 - S64
  • [8] UPDATED RESULTS FROM PHASE 2 STUDY OF GUADECITABINE FOR PATIENTS WITH UNTREATED INT-2/HIGH RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
    Montalban-Bravo, G.
    Bose, P.
    Alvarado, Y.
    Daver, N.
    Ravandi, F.
    Borthakur, G.
    Takahashi, K.
    Andreeff, M.
    Cortes, J.
    DiNardo, C.
    Jabbour, E. J.
    Kadia, T.
    Kornblau, S.
    Ohanian, M.
    Alfonso, A.
    Huang, X.
    Nogueras Gonzalez, G.
    Bodden, K.
    Pierce, S.
    Bueso-Ramos, C.
    Kantarjian, H.
    Garcia-Manero, G.
    HAEMATOLOGICA, 2017, 102 : 99 - 99
  • [9] UPDATED RESULTS FROM PHASE 2 STUDY OF GUADECITABINE FOR PATIENTS WITH UNTREATED INT-2/HIGH RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
    Montalban-Bravo, G.
    Prithviraj, B.
    Alvarado, Y.
    Daver, N.
    Ravandi, F.
    Borthakur, G.
    Takahashi, K.
    Andreeff, M.
    Cortes, J.
    DiNardo, C.
    Jabbour, E.
    Kadia, T.
    Kornblau, S.
    Ohanian, M.
    Nogueras-Gonzalez, G. M.
    Bodden, K.
    Pierce, S.
    Kantarjian, H.
    Garcia-Manero, G.
    LEUKEMIA RESEARCH, 2017, 55 : S25 - S26
  • [10] Initial Results of a Phase 2 Study of Guadecitabine (SGI-110), a Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)
    Montalban-Bravo, Guillermo
    Bose, Prithviraj
    Alvarado, Yesid
    Daver, Naval
    Ravandi, Farhad
    Borthakur, Gautam
    Takahashi, Koichi
    Andreeff, Michael
    Cortes, Jorge E.
    DiNardo, Courtney D.
    Jabbour, Elias
    Kadia, Tapan M.
    Kornblau, Steven M.
    Ohanian, Maro
    Pierola, Ana Alfonso
    Huang, Xuelin
    Nogueras-Gonzalez, Graciela M.
    Bodden, Kristy
    Littles, Kristina
    Pierce, Sherry
    Bueso-Ramos, Carlos E.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2016, 128 (22)
12345